Results 21 to 30 of about 146,743 (148)
Hematology, 2002 AbstractThis update provides new insights into the biology, diagnosis, prognosis, and treatment of multiple myeloma (MM) and its complications.In Section I, Drs. John Shaughnessy, Jr., and Bart Barlogie first correlate global gene microarray expression profiling of patient MM samples with normal plasma cells to provide the basis for a developmental ...
Kenneth C, Anderson +4 more
openaire +2 more sources
npj Precision Oncology, 2023 Optimal first-line treatment that enables deeper and longer remission is crucially important for newly diagnosed multiple myeloma (NDMM). In this study, we developed the machine learning (ML) models predicting overall survival (OS) or response of the ...
Sung-Soo Park +11 more
doaj +1 more source
Blood Cancer Journal, 2022 Chimeric antigen receptor T cells (CAR T) are groundbreaking therapies but may cause significant toxicities including cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and cytopenias.
Kevin Charles Miller +10 more
doaj +1 more source
Direct-to-patient research: Opportunity brings challenges
Cancer Treatment and Research CommunicationsDirect-to-patient (DTP) research offers promising alternatives to traditional models, potentially improving population-level data collection to understand disease initiation, progression, and response to treatment.
Anne Quinn-Young +8 more
doaj +1 more source
Widespread intronic polyadenylation diversifies immune cell transcriptomes
Nature Communications, 2018 Recognition of intronic polyadenylation (IpA) signals can lead to expression of truncated proteins lacking C terminal domains. Analysis of 3ʹ -seq and RNA-seq shows that IpA is widespread in circulating immune cells, while multiple myeloma cells show ...
Irtisha Singh +8 more
doaj +1 more source
The Emerging Role of Extracellular Vesicle-Associated RNAs in the Multiple Myeloma Microenvironment
Frontiers in Oncology, 2021 Multiple myeloma (MM) is a cancer of terminally differentiated plasma cells (PCs) that develop at multiple sites within the bone marrow (BM). MM is treatable but rarely curable because of the frequent emergence of drug resistance and relapse.
Jihane Khalife +4 more
doaj +1 more source
Blood Advances: Cast nephropathy is the most common cause of acute kidney injury (AKI) in patients with multiple myeloma (MM). A prompt reversal of renal injury is paramount for improving clinical outcomes.
E. Bridget Kim +9 more
doaj +1 more source
Blood Cancer JournalMultiple myeloma (MM) remains incurable despite novel therapeutics. A major contributor to the development of relapsed/refractory and resistant MM is extraosseous extramedullary disease (EMD), whose molecular biology is still not fully understood.
Rie Nakamoto-Matsubara +14 more
doaj +1 more source
Talquetamab in multiple myeloma
Haematologica, 2023 Initial results of the phase I trial of talquetamab, a bispecific antibody targeting GPRC5D and CD3, were reported in December of 2022 for the treatment of relapsed or refractory multiple myeloma in the fourth line or later setting.
Lawrence Liu, Amrita Krishnan
doaj +1 more source
Attrition rates and treatment outcomes in multiple myeloma: real-world data over a 40-year period
Blood Cancer JournalThe treatment landscape of multiple myeloma (MM) has evolved significantly over four decades, driven by novel therapies and optimized supportive care. However, the attrition rate (AR), defined as the proportion of patients who die without advancing to ...
Luis Gerardo Rodríguez-Lobato +12 more
doaj +1 more source